BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11521795)

  • 1. A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
    Knowling M; Browman G; Siu L; Khoo K; Cooke A; Tannock I; Klaassen D; Cripps C; Goss G; Matthews S; Clarke R; Seymour L
    Ann Oncol; 2001 Jul; 12(7):919-22. PubMed ID: 11521795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
    Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
    J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.
    Smith IE; Johnston SR; O'Brien ME; Hickish TF; de Boer RH; Norton A; Cirkel DT; Barton CM
    J Clin Oncol; 2000 Jun; 18(12):2378-84. PubMed ID: 10856097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
    Schilsky RL; Bukowski R; Burris H; Hochster H; O'Rourke M; Wall JG; Mani S; Bonny T; Levin J; Hohneker J
    Ann Oncol; 2000 Apr; 11(4):415-20. PubMed ID: 10847459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
    Jones SF; Greco FA; Hainsworth JD; Patton JW; Barton JH; Willcutt NT; Baker MN; McGuirt PV; Levin J; Burris HA
    Oncologist; 2002; 7(5):444-50. PubMed ID: 12401907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
    Marsh JC; Catalano P; Huang J; Graham DL; Cornfeld MJ; O'Dwyer PJ; Benson AB
    Clin Colorectal Cancer; 2002 May; 2(1):43-50. PubMed ID: 12453335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
    Mani S; Hochster H; Beck T; Chevlen EM; O'Rourke MA; Weaver CH; Bell WN; White R; McGuirt C; Levin J; Hohneker J; Schilsky RL; Lokich J
    J Clin Oncol; 2000 Aug; 18(15):2894-901. PubMed ID: 10920138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
    Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
    Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
    Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
    Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
    Schrijvers D; Van Herpen C; Kerger J; Joosens E; Van Laer C; Awada A; Van den Weyngaert D; Nguyen H; Le Bouder C; Castelijns JA; Kaanders J; De Mulder P; Vermorken JB
    Ann Oncol; 2004 Apr; 15(4):638-45. PubMed ID: 15033673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
    Levin J; Hohneker J
    Invest New Drugs; 2000 Nov; 18(4):383-90. PubMed ID: 11081574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
    Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
    Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.